PMID- 33768575
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1472-765X (Electronic)
IS  - 0266-8254 (Linking)
VI  - 73
IP  - 1
DP  - 2021 Jul
TI  - Metabolic syndrome cannot mask the changes of faecal microbiota compositions 
      caused by primary hepatocellular carcinoma.
PG  - 73-80
LID - 10.1111/lam.13477 [doi]
AB  - Both hepatocellular carcinoma (HCC) and metabolic syndrome are closely associated 
      with the composition of the gut microbiota (GM). Although it has been proposed 
      that elements of the GM can be used as biomarkers for the early diagnosis of HCC, 
      whether metabolic syndrome results in a misrepresentation of the results of the 
      early diagnosis of HCC using GM remains unclear. We compared the differences in 
      the faecal microbiota of 10 patients with primary HCC, six patients with type 2 
      diabetes mellitus (T2DM), seven patients with arterial hypertension, six patients 
      with both HCC and T2DM, and 10 patients with both HCC and arterial hypertension, 
      as well as 10 healthy subjects, using high-throughput sequencing of 16S rRNA gene 
      amplicons. Our results revealed a significant difference in the GM between 
      subjects with and without HCC. The 49 bacterial genera out of the 494 detected 
      genera were significantly different between the groups. These results show that 
      changes in the GM can be used to distinguish between subjects with and without 
      HCC, and can resist interference of T2DM and arterial hypertension with the GM. 
      The results of the present study provide an important basis for the clinical 
      auxiliary diagnosis of HCC by detecting the GM.
CI  - (c) 2021 The Society for Applied Microbiology.
FAU - Ni, J
AU  - Ni J
AUID- ORCID: 0000-0002-8875-4899
AD  - Research and Development Center, Guangdong Meilikang Bio-Sciences Ltd., Dongguan, 
      China.
AD  - Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center of 
      Artificial Organ and Tissue Engineering, Zhujiang Hospital of Southern Medical 
      University, Guangzhou, China.
AD  - Dongguan Key Laboratory of Medical Bioactive Molecular Developmental and 
      Translational Research, Guangdong Medical University, Dongguan, China.
FAU - Fu, C
AU  - Fu C
AD  - Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center of 
      Artificial Organ and Tissue Engineering, Zhujiang Hospital of Southern Medical 
      University, Guangzhou, China.
FAU - Huang, R
AU  - Huang R
AD  - Department of Neonatal Surgery, Guangdong Women and Children Hospital, Guangzhou, 
      China.
FAU - Li, Z
AU  - Li Z
AD  - Research and Development Center, Guangdong Meilikang Bio-Sciences Ltd., Dongguan, 
      China.
FAU - Li, S
AU  - Li S
AD  - Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center of 
      Artificial Organ and Tissue Engineering, Zhujiang Hospital of Southern Medical 
      University, Guangzhou, China.
FAU - Cao, P
AU  - Cao P
AD  - Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center of 
      Artificial Organ and Tissue Engineering, Zhujiang Hospital of Southern Medical 
      University, Guangzhou, China.
FAU - Zhong, K
AU  - Zhong K
AD  - Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center of 
      Artificial Organ and Tissue Engineering, Zhujiang Hospital of Southern Medical 
      University, Guangzhou, China.
FAU - Ge, M
AU  - Ge M
AD  - Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center of 
      Artificial Organ and Tissue Engineering, Zhujiang Hospital of Southern Medical 
      University, Guangzhou, China.
FAU - Gao, Y
AU  - Gao Y
AD  - Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center of 
      Artificial Organ and Tissue Engineering, Zhujiang Hospital of Southern Medical 
      University, Guangzhou, China.
AD  - State Key Laboratory of Organ Failure Research, Southern Medical University, 
      Guangzhou, China.
LA  - eng
GR  - 2015B020229002/Science and Technology Planning Project of Guangdong Province/
GR  - 2018YFA0108200/National Key R&D Program of China/
GR  - 2018YFC1106400/National Key R&D Program of China/
GR  - 2017M612691/China Postdoctoral Science Foundation/
PT  - Journal Article
DEP - 20210405
PL  - England
TA  - Lett Appl Microbiol
JT  - Letters in applied microbiology
JID - 8510094
RN  - 0 (Biomarkers)
RN  - 0 (RNA, Ribosomal, 16S)
SB  - IM
MH  - Adult
MH  - Bacteria/genetics
MH  - Biomarkers
MH  - Carcinoma, Hepatocellular/*diagnosis/*microbiology/pathology
MH  - Diabetes Mellitus, Type 2/microbiology
MH  - Feces/*microbiology
MH  - Female
MH  - Gastrointestinal Microbiome/*genetics
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Liver Neoplasms/*microbiology/pathology
MH  - Male
MH  - Metabolic Syndrome/*microbiology
MH  - Middle Aged
MH  - RNA, Ribosomal, 16S/genetics
OTO - NOTNLM
OT  - arterial hypertension
OT  - gut microbiota
OT  - hepatocellular carcinoma
OT  - metabolism syndrome
OT  - type 2 diabetes
EDAT- 2021/03/27 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/03/26 07:18
PHST- 2021/03/16 00:00 [revised]
PHST- 2020/12/24 00:00 [received]
PHST- 2021/03/22 00:00 [accepted]
PHST- 2021/03/27 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2021/03/26 07:18 [entrez]
AID - 10.1111/lam.13477 [doi]
PST - ppublish
SO  - Lett Appl Microbiol. 2021 Jul;73(1):73-80. doi: 10.1111/lam.13477. Epub 2021 Apr 
      5.